. A full list of GEO-PD consortium member sites is provided in the Supplementary Text.
Introduction
With an estimated prevalence of between 1% and 2% in individuals older than 65, Parkinson's disease (PD) is one of the most common age-related neurodegenerative disorders (de Lau and Breteler, 2006; Postuma and Montplaisir, 2009 ). Long thought of as a sporadic disease, PD now has a well-established genetic component which includes both disease-causing mutations as well as risk-modifying susceptibility variants . Of the PD susceptibility variants that have been identified thus far, the best validated have involved those located in the -synuclein (SNCA) gene, which also contains several pathogenic mutations that are linked to familial PD, and in the microtubule-associated protein tau (MAPT) gene . More specifically, associations with PD have been identified in both Caucasian and Asian populations at the 3 and 5 ends of the SNCA gene (Mizuta et al., 2006; Mueller et al., 2005; Pankratz et al., 2009; Ross et al., 2007; Satake et al., 2009; Simón-Sánchez et al., 2009; Winkler et al., 2007) , while the H1 haplotype in MAPT is associated with PD in Caucasians, but not in Asians owing to the almost complete absence of the H2 haplotype in that group (Evans et al., 2004; Healy et al., 2004; Skipper et al., 2004; Tobin et al., 2008; Wider et al., 2010) .
Variation in the leucine-rich repeat kinase 2 (LRRK2) gene, which like SNCA harbors disease-causing mutations of its own, has also been associated with susceptibility to PD in both Caucasian and Asian populations. The majority of proposed LRRK2 PD risk variants have been relatively rare (minor allele frequencies [MAFs] between 1% and 5%) and have included p.G2385R and p.R1628P in Asian populations as well as the more recently identified p.A419V (Asians), and p.M1646T (Caucasians) (Di Fonzo et al., 2006; Ross et al., 2008; Ross et al., 2011; Tan et al., 2010) . The most common LRRK2 PD risk factor to date, identified by several groups including our own, has involved a 3-variant (p.N551K-R1398H-K1423K) protective haplotype in both populations Tan et al., 2010) . It has been shown that the p.1398H variant has reduced kinase activity in comparison to the wild type p.R1398 (Tan et al. 2010) . Given these data, the p.R1398H (rs7133914) substitution, which occurs with a MAF of approximately 7% in Caucasians and 10% in Asians (Heckman et al., in press; Tan et al., 2010) , is the most likely functional variant on the haplotype. The protective effect of p.R1398H appears strongest in Asians, where consistent odds ratios of 0.75 and 0.73 have been observed in studies by Tan et al. (2010) and Ross et al. (2011) , with a similar odds ratio of 0.79 observed in a smaller study by Chen et al. (2011) . In Caucasians, the odds ratio for p.R1398H observed in the aforementioned study by Ross et al. in a series of 6995 patients and 5595 controls was 0.89. This is very similar to the findings of a large meta-analysis of genome-wide association studies, where although not nominally significant, LRRK2 p.R1398H (MAF~6.7%) had a protective odds ratio of 0.92 and 95% confidence limits ranging from 0.83 to 1.02 in regard to susceptibility to PD (Nalls et al. 2011; Personal Communication) .
In order to best determine risk of PD for a given individual and understand potential future therapeutic implications, it is important not only to identify individual genetic risk factors but also to understand how these risk factors interact with one another. However, sample sizes needed to reasonably evaluate evidence of such gene-gene interactions are usually fairly large and can be difficult to achieve. This is due to the fact that the risk factor of interest in an interaction study (presence of the genotype of interest for both variants) occurs much less frequently than the genotype for the individual variants, which can result in a lack of precision in estimated interaction effects. Collaboration between members of the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium and the resulting large number of patients with PD and controls offers the opportunity to effectively examine how recognized susceptibility variants for PD may or may not interact with one another. Such a study was previously undertaken by the GEO-PD Consortium, where SNCA and MAPT variants were examined in relation to risk of PD and found to have independent effects . The identification of PD susceptibility variants in LRRK2 raises the question of whether the effects of these variants may be modified by those in SNCA or MAPT, or vice versa. The aim of this study was to evaluate the interaction of the common LRRK2 susceptibility variant p.R1398H with SNCA and MAPT variants in relation to risk of PD using Caucasian and Asian patient-control series obtained through the GEO-PD Consortium.
Methods

Subjects
As of 2013, the GEO-PD Consortium includes 57 sites from 29 countries and six continents who have agreed to share DNA and data for 38,686 patients with PD and 34,871 control subjects (http://www.geopd.org/). A total of 20 sites participating in the GEO-PD Consortium provided data to be used in the current study as part of a project initiated in 2009. The majority of the Caucasian subjects utilized in this study were also included in the previously mentioned GEO-PD SNCA-MAPT interaction study , and the subjects included in this study are a subset of those included in the previously referred to investigation of LRRK2 exonic variants in relation to PD . To be consistent with the association analysis in the latter study involving LRRK2 exonic variants, carriers of LRRK2 pathogenic variants (N=64) were excluded. Subjects were not genotyped for known pathogenic SNCA mutations and therefore this was not part of our exclusion criteria. In total, 7,342 patients with PD and 5,269 controls from 13 different countries on 4 continents were studied, and these subjects were divided into a Caucasian series (5,991 patients with PD, 4,331 controls, 16 sites, 10 countries) and an Asian series (1,351 patients with PD, 938 controls, 4 sites, 3 countries). Patients were diagnosed with PD using standard criteria (Bower et al., 1999; Gelb et al., 1999; Hughes et al., 1992) . Controls were individuals free of PD or a related movement disorder at the time of examination. All subjects were unrelated within and between diagnosis groups. The Mayo Clinic Institutional Review Board approved the study, each individual site received local IRB approval, and all subjects provided informed consent.
Genetic analysis
Four SNCA variants (3 end of gene: rs181489, rs356219, rs11931074; 5 end of gene: rs2583988) as well as the MAPT H1-haplotype defining variant rs1052553 were genotyped due to consistently replicated associations with PD (Healy et al., 2004; Mizuta et al., 2006; Mueller et al., 2005; Pankratz et al., 2009; Ross et al., 2007; Satake et al., 2009; Skipper et al., 2004; Simón-Sánchez et al., 2009; Tobin et al., 2008; Wider et al., 2010; Winkler et al., 2007) . These five variants were chosen for the aforementioned GEO-PD SNCA-MAPT interaction study . The REP1 polymorphism located in the SNCA promoter has also been associated with PD (Krüger et al., 1999; Maraganore et al., 2006) , however due to the fact that the 263bp allele (which has shown the strongest association with PD) is relatively rare, we did not evaluate REP1 in the current study. The LRRK2 variant rs7133914 (p.R1398H) was also selected for inclusion due to the aforementioned findings demonstrating that is the most likely functional variant on a 3-variant haplotype (all 3 variants in strong linkage disequilibrium with r 2 >0.84 in controls) that affects risk of PD in a protective manner , Tan et al., 2010 .
DNA was sourced from blood and was stored in a −80°C freezer. All samples were deidentified with an anonymous code from each site and only a minimal clinical dataset. All LRRK2 and SNCA genotyping was done using MassArray iPLEX chemistry and analyzed using Typer 4.0 (Sequenom, San Diego, CA). MAPT rs1052553 was genotyped using an ABI Taqman genotyping assay on an ABI 7900HT Fast Real-Time PCR system and analyzed using SDS 2.2.2 software (Applied Biosystems, Foster City, CA, USA). All genotyping was performed at the Mayo Clinic Florida neurogenetics laboratory (Jacksonville, FL, USA). Primer sequences are provided in Supplementary Table 2 for all variants except for MAPT rs1052553. Positive control DNA was run for each variant. Call rates in each series were >95%. There was no evidence of departure from Hardy Weinberg Equilibrium in controls for any of the sites (all P>0.05 after Bonferroni correction).
Statistical analysis
All analysis was performed separately for the Caucasian and Asian series. Associations of individual SNCA variants, MAPT rs1052553, and LRRK2 p.R1398H with PD, and pairwise interactions of LRRK2 p.R1398H with SNCA and MAPT variants in relation to PD, were evaluated using odds ratios (ORs) and 95% confidence intervals (CIs) from fixedeffects logistic regression models adjusted for site. Interactions were evaluated on a multiplicative scale only because it has been shown that when at least one of the interacting factors is protective, biological interactions are expected to result in departure from multiplicative effects (Weinberg, 1986) .
We considered LRRK2 p.R1398H under a dominant model (presence vs. absence of the minor allele) in all analyses owing to the very small number of homozygotes of the minor allele, while SNCA variants were evaluated under an additive model (effect of each additional minor allele), dominant model, recessive model (presence of two copies vs. zero or one copy of the minor allele) and genotype model (general comparison across genotypes). MAPT rs1052553 was also evaluated under additive, dominant, recessive, and genotype models, but with effects corresponding to the major allele to be consistent with previous reports where ORs correspond to the H1 risk allele. In Caucasians, three-gene interactions were also examined. Sensitivity of results to model adjustment for age and gender and to the use of random-effects models (DerSimonian and Laird, 1986) were also assessed when evaluating interactions. Between-site heterogeneity in interaction ORs was examined using chi-square tests based on the Q statistic, and also by estimating the I 2 statistic, which measures the proportion of variation in interaction ORs between sites due to heterogeneity beyond chance (Higgins and Thompson, 2002) .
A relatively large number of statistical tests of gene-gene interaction were performed in our analyses (24 in the Caucasian series and 8 in the Asian series). In order to adjust for multiple testing and control the family-wise error rate at 5%, we employed a Bonferroni correction separately for each series, after which p-values≤0.0021 (Caucasian series) and ≤0.00625 (Asian series) were considered as statistically significant. All statistical analyses were performed using R Statistical Software (version 2.14.0; R Foundation for Statistical Computing, Vienna, Austria).
Results
A summary of allele and genotype frequencies for SNCA variants, MAPT rs1052553, and LRRK2 p.R1398H in our Caucasian and Asian patient-control series is provided in Supplementary Table 3 , along with country-specific frequencies. The SNCA variants rs181489 and rs2583988 as well as MAPT rs1052553 were observed extremely rarely in Asian patients and controls and as such were not assessed in association analysis. SNCA variants were in relatively weak linkage disequilibrium in controls (r 2 ≤ 0.32) with the exception of rs181489 and rs356219 in the Caucasian series (r 2 =0.58), rs181489 and rs2583988 in the Caucasian series (r 2 =0.53), and rs356219 and rs11931074 in the Asian series (r 2 =0.97).
In order to best interpret the results of gene-gene interaction analysis, it is helpful to first understand the effects of individual variants on risk of PD, and therefore single-variant associations with PD for the SNCA, MAPT, and LRRK2 variants, which have largely been reported before in the aforementioned GEO-PD studies , are displayed in Supplementary Table 4 . As has been previously shown, all variants were significantly associated with PD.
Evaluations of pair-wise interactions of LRRK2 p.R1398H with SNCA variants and MAPT rs1052553 in relation to PD for the Caucasian series are shown in Table 2 . To simplify our presentation of interaction results, we have focused on additive and genotype models for SNCA and MAPT variants in Table 2 since all of these variants had the strongest association with PD under an additive model except SNCA rs11931074 (which was also strongly associated with PD under an additive model), and because genotype models allow for the most general test of interaction. Gene-gene interactions under dominant and recessive models for SNCA and MAPT variants are shown in Supplementary Tables 5 and 6 . In siteadjusted analyses, no interactions of LRRK2 p.R1398H with SNCA and MAPT variants approached significance after multiple testing adjustment under any statistical model (all interaction P≥0.10); the protective effect of p.R1398H on risk of PD observed in similar magnitude for different genotypes of SNCA and MAPT variants, while the risk effects of SNCA and MAPT variants were seen similarly for subjects with and without a copy of the minor allele for p.R1398H. All interaction ORs were close to 1.0 in magnitude indicating lack of any interaction with LRRK2 p.R1398H, the only exceptions involving rare genotypes for MAPT rs1052553 under a dominant model (Supplementary Table 5 ) and SNCA rs11931074 under a recessive model (Supplementary Table 6 ) which are best interpreted with caution owing to the non-significant interactions and very low genotype frequencies. The lack of interaction of LRRK2 p.R1398H with MAPT and SNCA variants was also observed when adjusting for age and gender (Supplementary Table 7 ) in those subjects with that information available (98%) and also when utilizing a random effects model (Supplementary Table 8 ). Results of country-specific interaction analysis are shown in Supplementary Table 9 ; between-site heterogeneity regarding interactions with LRRK2 p.R1398H was low for SNCA rs356219, rs11931074, and rs2583988 (I 2 =0%, P≥0.45) and moderate for SNCA rs181489 and MAPT rs1052553 (I 2 =25% to 36%, P≥0.075) (Supplementary Table 8 ).
More detailed analysis combining genotypes across all three genes for SNCA variants, MAPT rs1052553, and LRRK2 p.R1398H in the Caucasian series is displayed in Supplementary Table 10 and Figure 1 , where rare homozygotes were collapsed with heterozygotes for each variant in order to avoid extremely rare three-variant genotype combinations. There was no evidence of any interaction in these three-gene analyses (all P≥0.63).
Interactions of LRRK2 p.R1398H with SNCA variants rs356219 and rs11931074 in the Asian series are examined in Table 3 in analysis adjusted for site. Individual effects of LRRK2 p.R1398H and SNCA variants on risk of PD were observed consistently across variants in the other gene, with no statistically significant evidence of gene-gene interaction (all interaction P≥0.14). All interaction ORs were between 1.17 and 1.39, indicating a slight but non-significant reduction of the protective effect of LRRK2 p.R1398H on risk of PD when the risk allele for SNCA variants was present, and a similar small and non-significant enhancement of the SNCA risk effects given the protective genotype for p.R1398H ( Figure   2 ). Results were similar when adjusting for age and gender (Supplementary 
Discussion
Recently, a 3-variant (p.N551K-R1398H-K1423K) haplotype in the LRRK2 gene was shown to affect susceptibility to PD in a protective manner in both Caucasian and Asian populations Tan et al., 2010) . The p.R1398H substitution appears to be the most likely functional variant as it is located in the conserved Roc domain and there is supporting evidence of reduced kinase activity (Tan et al., 2010) . While a number of previous investigations have examined interactions between the well-validated PD susceptibility variants located in the SNCA and MAPT genes (Biernacka et al., 2011; Elbaz et al., 2011; Goris et al., 2007; Mamah et al., 2005; McCulloch et al., 2008; Simón-Sánchez et al., 2009; Trotta et al., 2012; Wider et al., 2011) , no report to date has examined interactions of LRRK2 p.R1398H with SNCA and MAPT variants. The results of our large case-control study involving both Caucasian and Asian individuals indicate that the protective effect of LRRK2 p.R1398H is observed consistently for different SNCA and MAPT genotypes, while similarly, the SNCA and MAPT risk effects are observed for individuals with and without the protective p.R1398H allele.
Despite the relatively large number of interactions and statistical models considered, the independent effects on PD risk for LRRK2 p.R1398H, MAPT rs1052553, and SNCA variants were observed with a very high level of consistency in our study. This was most apparent in the large Caucasian series, where all interaction odds ratios were between 0.80 and 1.13, with the exception of the two aforementioned instances involving rare genotypes for MAPT rs1052553 and SNCA rs11931074. Additionally, between-site heterogeneity in interaction effects was low to moderate in Caucasians. Although the protective effect of LRRK2 p.R1398H on risk of PD was observed consistently across SNCA variant genotypes in Asians, perhaps the least convincing evidence of lack of gene-gene interaction was observed in this series. Though not approaching significance even before adjustment for multiple testing, the magnitude of this observed protective effect was slightly smaller when the risk genotype for SNCA variants was present, while conversely the observed risk effects of SNCA variants were marginally stronger in individuals with the protective p.R1398H genotypes. Additionally, heterogeneity in interaction effects between sites was highest in the Asian series. However, it is important to highlight that it would be very unusual to observe a complete lack of gene-gene interaction (i.e. interaction odds ratio equal to 1) in all scenarios simply due to natural sampling variability, particularly given the number of possible interactions that were examined. Nonetheless, given the smaller size of our Asian series in comparison to the Caucasian series, it will be important to validate our findings in larger series of Asian individuals.
Recent studies have supported our earlier work indicating that the effects of SNCA and MAPT variants on PD risk are independent of one another (Biernacka et al., 2011; Trotta et al., 2012; Wider et al., 2011 ). Though our current study is the first to date to examine the potential interaction of the protective LRRK2 p.R1398H substitution with MAPT and SNCA variants in regard to risk of PD, previous studies have evaluated interactions with, or combined effects of, LRRK2 variants and those in SNCA and MAPT. In their analysis of 1098 patients with PD and 1098 matched controls from the United States (a subset of which were also used in the current study), Biernacka et al. (2011) found no statistically significant evidence of gene-gene interaction when considering 8 intronic LRRK2 variants, 10 SNCA variants (eight intronic, one 3 downstream, and 5 Rep1), and 8 MAPT variants (six intronic, one 3 UTR, and H1/H2). Wang et al. (2012) concluded that other genes, including MAPT and SNCA, modified LRRK2-related risk for PD in a Chinese cohort of 2,013 sporadic PD patients and 1,971 controls. This was based on findings that in comparison to individuals harboring only the LRRK2 p.G2385R or p.R1628P risk variants, the risk of PD is increased in individuals with these and other PD risk variants. However, it is unclear whether this represents independent or interactive effects, and the sample sizes of the combined risk-variant groups examined were quite small. The results of these studies are consistent with those of our own, with the effect of LRRK2 variants on PD susceptibility appearing to be independent of SNCA and MAPT risk factors for PD.
While the strengths of our study, including the large sample size and inclusion of subjects from a variety of different populations, are important to highlight, several limitations should also be acknowledged. A key question is whether the lack of interaction of LRRK2 p.R1398H with SNCA and MAPT variants is a consequence of sample size or the frequencies of the examined variants. In order to assess the possibility of a false-negative association, it is most helpful to examine 95% confidence limits for observed interaction odds ratio estimates (Goodman and Berlin, 1994) . These confidence limits were generally relatively tight in the larger Caucasian series indicating a lack of a biologically significant interaction in this population, but were wider in the Asian series, further highlighting the need for validation of our findings in that series. Additionally, as is generally the case for large-scale collaborative studies attempting to address a focused research question that involves a small number of genetic variants, without available genome-wide population control markers, population stratification could potentially have had an impact on our results. However, this potential limitation is lessened by the fact that our logistic regression models were adjusted by site, which makes any possible population stratification a sitespecific issue. Other limitations of our study include the different diagnostic criteria across the different sites and the lack of a standardized inclusion/exclusion criteria for patients with PD and controls.
In conclusion, our study provides evidence that the effect of LRRK2 p.R1398H on risk of PD is independent of the MAPT H1-haplotype defining variant rs1052553 and SNCA variants, and vice versa. This lack of gene-gene interaction was apparent in both our large Caucasian patient-control series and our smaller Asian series. Evaluation of interactions involving individuals of other ethnic backgrounds, other rarer LRRK2 susceptibility variants, and PD susceptibility variants at other loci (Lill et al., 2012 ) is needed in order to move toward a fuller understanding of the genetic architecture of PD susceptibility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. A) Individual and combined effects of SNCA rs181489, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs181489, the risk genotype was CT or TT (i.e. presence of the minor allele); B) Individual and combined effects of SNCA rs356129, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs356129, the risk genotype was AG or GG (i.e. presence of the minor allele); C) Individual and combined effects of SNCA rs11931074, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs11931074, the risk genotype was GT or TT (i.e. presence of the minor allele); D) Individual and combined effects of SNCA rs2583988, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series. For SNCA rs2583988, the risk genotype was CT or TT (i.e. presence of the minor allele). Figures 1A-1D ) For MAPT rs1052553, the risk genotype was AA (i.e. presence of two copies of the major allele); for LRRK2 p.R1398H, the protective genotype was GA or AA (i.e. presence of the minor allele); NA indicates that a given SNP was not involved in the particular portion of the analysis. A) Individual and combined effects of SNCA rs356219, SNCA rs11931074, and LRRK2 p.R1398H on risk of PD in the Asian series. SNCA rs356219 and rs11931074 were considered under a recessive model (i.e. presence vs. absence of two copies of the minor allele). For SNCA rs356219, the risk genotype was GG. For SNCA rs11931074, the risk genotype was TT; B) Individual and combined effects of SNCA rs356219, SNCA rs11931074, and LRRK2 p.R1398H on risk of PD in the Asian series. SNCA rs356219 and rs11931074 were considered under a dominant model (i.e. presence vs. absence of the minor allele). For SNCA rs356219, the risk genotype was AG or GG. For SNCA rs11931074, the risk genotype was GT or TT. Figures 2A-2B ) For LRRK2 p.R1398H, the protective genotype was GA or AA (i.e. presence of the minor allele); NA indicates that a given SNP was not involved in the particular portion of the analysis. ORs and p-values result from fixed-effects logistic regression models. For tests of association, the two given variants were combined into one variable, and the model was adjusted for site. For tests of interaction, models included each of the two variants, their interaction, and site. Additive models, genotype models, dominant models, and recessive models refer to the characterization of SNCA variants;
only dominant models were considered for LRRK2 p.R1398H due to the small number of rare homozygotes for this variant. 1
Interaction ORs under an additive model are interpreted as the multiplicative increase in the effect of the minor allele for LRRK2 p.R1398H on PD corresponding to each additional risk allele for SNCA variants, or alternatively as the as the multiplicative increase in the effect of each additional risk allele for SNCA variants on PD corresponding to presence of the minor allele for LRRK2 p.R1398H.
2
Interaction ORs under a dominant model are interpreted as the multiplicative increase in the effect of the minor allele for LRRK2 p.R1398H on PD corresponding to presence of the risk allele for SNCA variants, or alternatively as the as the multiplicative increase in the effect of presence of the risk allele for SNCA variants on PD corresponding to presence of the minor allele for LRRK2 p.R1398H..
3
Interaction ORs under a recessive model are interpreted as the multiplicative increase in the effect of the minor allele for LRRK2 p.R1398H on PD corresponding to presence of two risk alleles for SNCA variants, or alternatively as the as the multiplicative increase in the effect of presence of two risk alleles for SNCA variants on PD corresponding to presence of the minor allele for LRRK2 p.R1398H.
4
Tests of interaction under a genotype model do not produce a single interaction OR, and therefore only a p-value is given. OR=odds ratio. CI=confidence interval.
